Absci Corp
NASDAQ:ABSI
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.25
6.585
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ABSI stock under the Base Case scenario is 1.51 USD. Compared to the current market price of 3.99 USD, Absci Corp is Overvalued by 62%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Absci Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ABSI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Absci Corp
Balance Sheet Decomposition
Absci Corp
Current Assets | 165.2m |
Cash & Short-Term Investments | 145.2m |
Receivables | 44k |
Other Current Assets | 19.9m |
Non-Current Assets | 90.3m |
PP&E | 41m |
Intangibles | 46.6m |
Other Non-Current Assets | 2.8m |
Current Liabilities | 25.5m |
Accounts Payable | 1.7m |
Accrued Liabilities | 18.5m |
Other Current Liabilities | 5.3m |
Non-Current Liabilities | 8.6m |
Long-Term Debt | 3.1m |
Other Non-Current Liabilities | 5.4m |
Earnings Waterfall
Absci Corp
Revenue
|
3.2m
USD
|
Operating Expenses
|
-101.5m
USD
|
Operating Income
|
-98.3m
USD
|
Other Expenses
|
6m
USD
|
Net Income
|
-92.3m
USD
|
Free Cash Flow Analysis
Absci Corp
USD | |
Free Cash Flow | USD |
Absci announced a new partnership with Memorial Sloan Kettering Cancer Center, aiming to develop up to six therapeutic programs. Progress was also noted on internal assets ABS-101, ABS-201, and ABS-301. ABS-101 showed significantly extended half-life in studies. For Q2 2024, Absci reported $1.3 million in revenue with increased R&D expenses of $15.3 million. Despite higher expenses, cash reserves stood at $145.2 million, projected to fund operations into H1 2027. The company expects to secure three more partnerships by year-end, enhancing its diversified portfolio.
What is Earnings Call?
ABSI Profitability Score
Profitability Due Diligence
Absci Corp's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Absci Corp's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
ABSI Solvency Score
Solvency Due Diligence
Absci Corp's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Absci Corp's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABSI Price Targets Summary
Absci Corp
According to Wall Street analysts, the average 1-year price target for ABSI is 8.45 USD with a low forecast of 6.06 USD and a high forecast of 13.65 USD.
Dividends
Current shareholder yield for ABSI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
Contact
IPO
Employees
Officers
The intrinsic value of one ABSI stock under the Base Case scenario is 1.51 USD.
Compared to the current market price of 3.99 USD, Absci Corp is Overvalued by 62%.